PWMS News Search Results

Back to NewsWire Home
Back to
  Back to PeopleWithMS NewsWire 

April 2008 Off the Wire . . .




Acute promyelocytic leukemia after mitoxantrone therapy for multiple sclerosis.

Article provided by: PubMed
Article Date: 2008 Apr 15

Department of Internal Medicine, Rochester General Hospital, Rochester, NY 14621.

Mitoxantrone is a DNA-topoisomerase 2 inhibitor used as a single agent for treatment of relapsing-remitting or progressive multiple sclerosis (MS). We present here two patients treated with mitoxantrone for MS who subsequently developed acute promyelocytic leukemia (APL). These constitute, to our knowledge, the eighth and ninth reports of APL in patients treated with mitoxantrone for MS. Topoisomerase 2 inhibitors are associated with therapy-related acute myeloid leukemia (t-AML) with 11q23 abnormalities, but therapy-related APL (t-APL) is less common, and documentation of nine cases of t-APL after mitoxantrone therapy for MS suggests a specific association.

E-Mail the NewsWire e-mail the NewsWire ! ! ! - Handpainted and Customized Canes
 with any news items you discover 

copyright 2003